echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Overview of clinical projects of cancer cell immunotherapy: over 2000 pipelines CAR-...

    Overview of clinical projects of cancer cell immunotherapy: over 2000 pipelines CAR-...

    • Last Update: 2021-06-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cellular immunotherapy for cancer is a therapy in which normal or bioengineered human cells are transplanted or transferred into the body of cancer patients to achieve the effect of cancer treatment


    Recently, IQVIA, a world-renowned medical industry consulting company, and the non-profit organization Cancer Research Institute (CRI) published an analyst report titled The clinical pipeline for cancer cell therapies in Nature Reviews Drug Discovery, a subsidiary of Nature, describing It shows the current global clinical research and development picture of cancer cell immunotherapy


    CAR-T therapy is still the mainstream, and the application of allogeneic cells is growing rapidly

    CAR-T therapy is still the mainstream, and the application of allogeneic cells is growing rapidly

    The main types of cellular immunotherapy include CAR-T, TCR-transduced T cells (TCR-T), tumor infiltrating lymphocytes (TIL) and natural killer (NK) cells, etc.


    Picture from Frost & Sullivan analysis

    Picture from Frost & Sullivan analysis

    From this report, the global cell therapy pipeline is steadily advancing.


    Comparison of cell therapies at different clinical stages from 2019 to 2021

    Comparison of cell therapies at different clinical stages from 2019 to 2021

    Among more than 2,000 cell therapies, CAR-T is still the mainstream, with 299 new clinical pipelines, an increase of 35% over 2020, and most (80%) pipelines are in preclinical or clinical phase 1


    Changes in the pipeline of cellular immunotherapy from 2019 to 2021

    Changes in the pipeline of cellular immunotherapy from 2019 to 2021

    CD19, BCMA, etc.


    CD19, BCMA, etc.


    Judging from the five products approved by the FDA, CD19 with four listed drugs and BCMA with one listed product are undoubtedly one of the hottest tracks


    Popular targets in the field of hematoma

    Popular targets in the field of hematoma

    From the perspective of solid tumors, the research target remains basically unchanged, and the number of undisclosed tumor-associated antigens (TAA) still tops the list


    Popular targets for solid tumors

    Popular targets for solid tumors

    China and the United States are leading the world in research projects, solid tumors are still difficult to treat

    China and the United States are leading the world in research projects, solid tumors are still difficult to treat

    The report pointed out that according to the data of ClinicalTrials.


    At present, the United States is still the leader in cellular immunotherapy, with 791 cell therapy projects in progress, and China’s domestic enthusiasm for cellular immunotherapy is not inferior, with the number of projects reaching 695.


    Global overview of cell therapy drugs by sponsor (academic institutions and pharmaceutical manufacturers)

    Global overview of cell therapy drugs by sponsor (academic institutions and pharmaceutical manufacturers)

    Cancer is currently one of the hottest tracks for venture capital in the medical and health field, and cellular immunotherapy is considered one of the most promising innovative therapies to overcome tumors


    Reference materials:

    Reference materials:

    [1]https://

    [1]https://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.